Discover open access scientific publications

Search, annotate, share and cite publications

Publications by T.G. Martin

Preliminary Results of a Phase 1 Dose Escalation Study of the First-In-Class Anti-Cd74 Antibody Drug Conjugate (Adc), Stro-001, in Advanced B-Cell Malignancies

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Related publications

A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies

Cancer
Cancer ResearchOncology
2018English

Anti-Pd-1 Monoclonal Antibody MEDI0680 in a Phase I Study of Patients With Advanced Solid Malignancies

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2019English

A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2017English

Ono-4059 (Gs-4059), a Next Generation BTK Inhibitor, Monotherapy in Patients With B-Cell Malignancies in the Japanese Phase 1, Dose-Escalation Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Phase 1 Trials of Anti-Enpp3 Antibody Drug Conjugates in Advanced Refractory Renal Cell Carcinomas

Clinical Cancer Research
Cancer ResearchOncology
2018English

Safety and Pharmacokinetics of MM-302, a HER2-targeted Antibody–liposomal Doxorubicin Conjugate, in Patients With Advanced HER2-positive Breast Cancer: A Phase 1 Dose-Escalation Study

British Journal of Cancer
Cancer ResearchOncology
2018English

Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

British Journal of Haematology
Hematology
2010English

P1.01-37 BPI-9016M, a Novel C-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results From a First-In-Human, Phase 1, Dose-Escalation Study

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Phase I Study of the Anti-FcRH5 Antibody-Drug Conjugate DFRF4539A in Relapsed or Refractory Multiple Myeloma

Blood Cancer Journal
OncologyHematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy